An updated expert consensus on childhood nocturnal enuresis (NE) offers a new framework to improve diagnosis and treatment, potentially helping millions of children and their families. Published in the World Journal of Pediatrics, the guidance includes 18 recommendations that aim to standardize care while tailoring it to each child’s specific condition.
Nocturnal enuresis, commonly known as bed-wetting, affects a significant number of school-age children. Beyond the inconvenience, persistent bed-wetting can harm self-esteem, disrupt sleep, and strain family relationships. Despite available effective treatments, underdiagnosis and inconsistent practice have limited outcomes. In China, regional differences in healthcare access, cultural perceptions, and coordination between primary and specialist services add further complexity.
Since the previous Chinese consensus in 2014, international standards and the evidence base have evolved substantially. The new consensus, developed by researchers from the Children’s Hospital of Fudan University and other Chinese experts, addresses these changes. It is published in the World Journal of Pediatrics with the DOI: 10.1007/s12519-026-01051-4.
Key updates include lowering the diagnostic frequency threshold. Children aged five years or older now qualify for diagnosis if they experience at least one involuntary nighttime void per month for three months, a shift from the previous weekly standard. This allows for earlier intervention. The consensus also mandates a clear distinction between monosymptomatic NE (MNE), where no daytime symptoms are present, and non-monosymptomatic NE (NMNE), which includes daytime symptoms like urgency or incontinence. This classification guides treatment decisions.
The voiding diary becomes a cornerstone of diagnosis. Patients must record at least two daytime charts and seven consecutive nights of fluid intake and voids. This helps clinicians phenotype children as having nocturnal polyuria, reduced bladder capacity, or both. For MNE, first-line therapy is phenotype-driven: desmopressin for nocturnal polyuria and enuresis alarm for reduced bladder capacity, with combination therapy for mixed types. For NMNE, management prioritizes daytime lower urinary tract symptoms and comorbidities, especially constipation, which affects 36–80% of these children.
The consensus also outlines clear referral criteria. Primary care can manage MNE, but non-responders or suspected NMNE require specialist evaluation with urodynamics and lumbosacral magnetic resonance imaging (MRI). For refractory cases, defined as less than 50% improvement after three months, the advice is to systematically re-evaluate adherence, diary findings, and underlying causes before escalating treatment.
The authors emphasize that NE should not be treated as a uniform disorder. The updated pathway asks clinicians to identify the child’s specific pattern, look for daytime symptoms and comorbidities, and match treatment to the underlying mechanism while involving the family. Apparent treatment failure should trigger a careful review before adding stronger therapy.
In practice, these recommendations could help pediatricians and primary-care clinicians identify which children can be managed locally and which need specialist assessment. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error treatment. Earlier attention to constipation, sleep-disordered breathing, attention-deficit/hyperactivity disorder (ADHD), and daytime urinary symptoms could improve response rates. The framework also encourages timely referral when first-line therapy fails or NMNE is suspected, supporting better coordination across levels of care.
The authors acknowledge that some recommendations reflect Chinese practice patterns, and evidence remains limited for areas like desmopressin withdrawal strategies. Future trials and multidisciplinary care models could further refine individualized treatment. The original source can be found at this link.
